APP Mutations in Alzheimer's Disease

APP Mutations in Alzheimer's Disease

Overview

App Mutations In [Alzheimer'S Disease](/diseases/alzheimers-disease) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Introduction

App Mutations In Alzheimer'S Disease represents an important genetic factor in neurodegenerative disease research. This page provides comprehensive information about its role in disease mechanisms, genetic associations, and therapeutic implications. [@mapping]

Mutations in the [Amyloid Precursor Protein](/entities/app-protein) (APP) gene cause autosomal dominant familial Alzheimer's disease, providing critical insights into [amyloid-beta](/proteins/amyloid-beta) pathogenesis. [@molecular]

Genetic Background

• Gene: APP (Amyloid Precursor Protein)
• Chromosome: 21q21.3
• Inheritance: Autosomal dominant
• Mutation Count: >40 pathogenic mutations identified
• Prevalence: ~10-15% of familial AD cases

Normal APP Function

APP is a transmembrane glycoprotein with diverse physiological functions: [@compromised]

• Neuronal development: Promotes neurite outgrowth and synaptic formation
• Synaptic plasticity: Modmission
• ulates excitatory: BMetal homeostasis neurotransinds copper, zinc, and iron
• Cellular stress response: Activates protective pathways

Proteolytic Processing

APP is cleaved by three secretases: [@differences]

...

APP Mutations in Alzheimer's Disease

Overview

App Mutations In [Alzheimer'S Disease](/diseases/alzheimers-disease) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Introduction

App Mutations In Alzheimer'S Disease represents an important genetic factor in neurodegenerative disease research. This page provides comprehensive information about its role in disease mechanisms, genetic associations, and therapeutic implications. [@mapping]

Mutations in the [Amyloid Precursor Protein](/entities/app-protein) (APP) gene cause autosomal dominant familial Alzheimer's disease, providing critical insights into [amyloid-beta](/proteins/amyloid-beta) pathogenesis. [@molecular]

Genetic Background

• Gene: APP (Amyloid Precursor Protein)
• Chromosome: 21q21.3
• Inheritance: Autosomal dominant
• Mutation Count: >40 pathogenic mutations identified
• Prevalence: ~10-15% of familial AD cases

Normal APP Function

APP is a transmembrane glycoprotein with diverse physiological functions: [@compromised]

• Neuronal development: Promotes neurite outgrowth and synaptic formation
• Synaptic plasticity: Modmission
• ulates excitatory: BMetal homeostasis neurotransinds copper, zinc, and iron
• Cellular stress response: Activates protective pathways

Proteolytic Processing

APP is cleaved by three secretases: [@differences]

| Secretase | Cleavage Site | Products |
|-----------|---------------|----------|
| α-secretase | [Aβ](/proteins/amyloid-beta) domain (Residue 16) | sAPPα, CTFα (non-amyloidogenic) |
| [β-secretase](/entities/bace1) (BACE1) | N-terminus of Aβ | sAPPβ, CTFβ |
| [γ-secretase](/entities/gamma-secretase) | Transmembrane domain | Aβ peptides (Aβ40, Aβ42) |

Pathogenic Mutations

Mechanism Categories

APP mutations cause AD through two primary mechanisms:

Increased Aβ Production: Mutations near β- or γ-secretase cleavage sites

Altered Aβ Aggregation: Mutations within the Aβ sequence affecting fibril formation

Major Mutations

Swedish Mutation (APPswe)

• Location: Aβ1-2 (KM→NL at positions -2/-1)
• Effect: 3-6x increased Aβ production via enhanced β-secretase cleavage
• Age of Onset: ~50-60 years
• Reference: [Mullan et al., 1992](https://pubmed.ncbi.nlm.nih.gov/1311769)

Flemish Mutation (APPswe)

• Location: Aβ21 (A→G, "Flemish")
• Effect: Increased Aβ production, reduced aggregation
• Age of Onset: ~50-60 years
• Reference: [Hendriks et al., 1992](https://pubmed.ncbi.nlm.nih.gov/1314356)

Arctic Mutation

• Location: Aβ22 (E22G, "Arctic")
• Effect: Enhanced Aβ aggregation into protofibrils
• Phenotype: Typical AD progression
• Reference: [Nilsberth et al., 2001](https://pubmed.ncbi.nlm.nih.gov/11739428)

Dutch Mutation

• Location: Aβ21 (E22Q, "Dutch")
• Effect: Hereditary cerebral hemorrhage with amyloidosis (HCHWA-D)
• Phenotype: Recurrent cerebral hemorrhages, cognitive decline
• Reference: [Levy et al., 1990](https://pubmed.ncbi.nlm.nih.gov/1978547)

Iowa Mutation

• Location: Aβ24 (D23N, "Iowa")
• Effect: Enhanced Aβ40 aggregation, cerebral amyloid angiopathy
• Phenotype: CAA, cerebral hemorrhage, cognitive impairment
• Reference: [Grabowski et al., 2001](https://pubmed.ncbi.nlm.nih.gov/11452365)

London Mutation

• Location: Aβ37 (V717I, "London")
• Effect: Increased Aβ42/Aβ40 ratio
• Age of Onset: ~55-60 years
• Reference: [Chartier-Harlin et al., 1991](https://pubmed.ncbi.nlm.nih.gov/1906839)

Italian Mutation

• Location: Aβ37 (V717I, same as London, independent)
• Effect: Increased Aβ42 production
• Reference: [Matsumura et al., 1992](https://pubmed.ncbi.nlm.nih.gov/1572786)

Austrian Mutation

• Location: APP 692 (A692G, Austrian)
• Effect: Similar to Flemish, increased Aβ production
• Reference: [Carter et al., 1992](https://pubmed.ncbi.nlm.nih.gov/1572787)

French Mutation

• Location: APP 693 (E693G, "French")
• Effect: Arctic-like, promotes protofibril formation
• Reference: [Pasalar et al., 2002](https://pubmed.ncbi.nlm.nih.gov/12023580)

Piedmont Mutation

• Location: L723P (APP "Piedmont")
• Effect: Increased Aβ42/Aβ40 ratio
• Reference: [Eckman et al., 1997](https://pubmed.ncbi.nlm.nih.gov/9394008)

Down Syndrome (Trisomy 21)

Individuals with Down syndrome have three copies of APP (gene dosage effect):

• Aβ accumulation: Begins in 2nd-3rd decade
• AD incidence: ~50-70% develop dementia by age 60
• Mechanism: 1.5x APP expression → increased Aβ production

Neuropathology

Amyloid Pathology

• Plaque deposition: Predominantly diffuse and cored plaques
• Vascular involvement: Cerebral amyloid angiopathy (CAA) in some mutations
• Regional distribution: [Cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), basal ganglia

Downstream Effects

• Synaptic loss: Early and prominent
• Neurofibrillary tangles: [Tau](/proteins/tau) pathology follows amyloid deposition
• Neuronal death: Progressive, especially in hippocampus
• Neuroinflammation: Microglial activation around plaques

Therapeutic Implications

APP as Drug Target

BACE inhibitors: Block Aβ production at source

• Failed trials: Verubecestat, Lanabecestat, Atabecestat
• Challenge: Essential BACE functions in myelination

γ-secretase modulators: Shift cleavage toward shorter Aβ peptides

• Development ongoing

Anti-Aβ antibodies: Clear existing plaques

• [Lecanemab](/entities/lecanemab): Binds Aβ protofibrils
• [Donanemab](/entities/donanemab): Targets N-terminal Aβ

Mutation-Specific Considerations

| Mutation | Therapeutic Implication |
|----------|-------------------------|
| Swedish | BACE inhibitor responsive |
| Arctic | Anti-aggregation drugs |
| Dutch/Iowa | CAA-focused approaches |
| All | Anti-Aβ immunotherapies |

• [APP Gene](/Genes/APP)
• [Proteins/APP Protein](/proteins/app)
• [Alzheimer's disease](/diseases/alzheimers-disease)
• [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-pathway)
• [PSEN1](/entities/psen1) Mutations in AD
• [PSEN2](/entities/psen2) Mutations in AD
• Down Syndrome and Alzheimer's Disease

Overview

App Mutations In Alzheimer'S Disease plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Background

The study of App Mutations In Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [Human in vitro and rodent in vivo models highlight progressive mitochondrial dysfunction as a starting point of cerebral amyloidosis.](https://pubmed.ncbi.nlm.nih.gov/41637762/) (2026 May) - Neurobiology of aging
• [Mapping dementia research in Morocco: A scoping review of epidemiological, genetic, and therapeutic evidence.](https://pubmed.ncbi.nlm.nih.gov/41804744/) (2026 Mar 10) - Journal of Alzheimer's disease : JAD
• [Molecular Complexities of Dementia: PAISA Mutations and Targeting TAF2N as Therapeutic Avenues.](https://pubmed.ncbi.nlm.nih.gov/41820211/) (2026 Mar 3) - Current gene therapy
• [Compromised synaptic signal from prefrontal cortex to mediodorsal thalamus in Alzheimer's disease models and its rescue by kinase inhibitors.](https://pubmed.ncbi.nlm.nih.gov/41691604/) (2026 Mar) - The Journal of physiology
• [Differences in hearing across the lifespan in two strains of Alzheimer's mouse models as measured using behavioral and physiological techniques.](https://pubmed.ncbi.nlm.nih.gov/41650876/) (2026 Mar) - Hearing research

References